Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
L126243-5mg | 5mg | In stock | $28.90 | |
L126243-10mg | 10mg | In stock | $48.90 | |
L126243-25mg | 25mg | In stock | $100.90 | |
L126243-50mg | 50mg | In stock | $163.90 | |
L126243-100mg | 100mg | In stock | $263.90 | |
L126243-250mg | 250mg | In stock | $594.90 | |
L126243-1g | 1g | In stock | $2,138.90 | |
L126243-5g | 5g | In stock | $9,622.90 |
Synonyms | LESINURAD|878672-00-5|RDEA594|RDEA 594|Zurampic|RDEA-594|2-((5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-yl)thio)acetic acid|UNII-09ERP08I3W|Lesinurad free acid|(+)-Lesinurad|(-)-Lesinurad|09ERP08I3W|Lesinurad, (+)-|Lesinurad, (-)-|Lesinur |
---|---|
Specifications & Purity | Moligand™, ≥98% |
Biochemical and Physiological Mechanisms | Lesinurad is a selective inhibitor of Urate transporter 1 (URAT1), a urate-anion exchanger which is responsible for the majority of uric acid reabsorption from the renal tubular lumen. Lesinurad thus reduces serum uric acid levels. Lesinurad has been appr |
Storage Temp | Store at -20°C |
Shipped In | Ice chest + Ice pads |
Grade | Moligand™ |
Action Type | INHIBITOR |
Mechanism of action | Solute carrier family 22 member 12 inhibitor |
Note | 5mg、50mg、10mg卖完停产,不再备货 |
Product Description | Lesinurad(RDEA594), once-daily inhibitor of URAT1, is a transporter in the kidney that regulates uric acid excretion from the body. |
ALogP | 4.7 |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Pubchem Sid | 488201641 |
---|---|
Pubchem Sid Url | https://pubchem.ncbi.nlm.nih.gov/substance/488201641 |
IUPAC Name | 2-[[5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-1,2,4-triazol-3-yl]sulfanyl]acetic acid |
INCHI | InChI=1S/C17H14BrN3O2S/c18-16-19-20-17(24-9-15(22)23)21(16)14-8-7-11(10-5-6-10)12-3-1-2-4-13(12)14/h1-4,7-8,10H,5-6,9H2,(H,22,23) |
InChi Key | FGQFOYHRJSUHMR-UHFFFAOYSA-N |
Canonical SMILES | C1CC1C2=CC=C(C3=CC=CC=C23)N4C(=NN=C4Br)SCC(=O)O |
Isomeric SMILES | C1CC1C2=CC=C(C3=CC=CC=C23)N4C(=NN=C4Br)SCC(=O)O |
PubChem CID | 53465279 |
Molecular Weight | 404.28 |
CAS Registry No. | 878672-00-5 |
---|---|
PubChem CID | 53465279 |
ChEMBL Ligand | CHEMBL2105720 |
DrugCentral Ligand | 5075 |
PubChem SID | 488201641 |
Enter Lot Number to search for COA:
To view the certificate results,please click on a Lot number.For Lot numbers from past orders,please use our order status section
Lot Number | Certificate Type | Date | Item |
---|---|---|---|
J1521092 | Certificate of Analysis | Jun 09, 2023 | L126243 |
E23061055 | Certificate of Analysis | Apr 20, 2023 | L126243 |
E23061057 | Certificate of Analysis | Apr 20, 2023 | L126243 |
E23061058 | Certificate of Analysis | Apr 20, 2023 | L126243 |
E23061060 | Certificate of Analysis | Apr 20, 2023 | L126243 |
E23061061 | Certificate of Analysis | Apr 20, 2023 | L126243 |
E23061063 | Certificate of Analysis | Apr 20, 2023 | L126243 |
E23061065 | Certificate of Analysis | Apr 20, 2023 | L126243 |
E23061066 | Certificate of Analysis | Apr 20, 2023 | L126243 |
E23061067 | Certificate of Analysis | Apr 20, 2023 | L126243 |
E23061068 | Certificate of Analysis | Apr 20, 2023 | L126243 |
E23061069 | Certificate of Analysis | Apr 20, 2023 | L126243 |
E23061070 | Certificate of Analysis | Apr 20, 2023 | L126243 |
E23061073 | Certificate of Analysis | Apr 20, 2023 | L126243 |
E23061082 | Certificate of Analysis | Apr 20, 2023 | L126243 |
Solubility | 25°C: DMSO |
---|
Pictogram(s) | GHS07 |
---|---|
Signal | Warning |
Hazard Statements | H302:Harmful if swallowed |
Precautionary Statements | P501:Dispose of contents/container to ... P264:Wash hands [and …] thoroughly after handling. P270:Do not eat, drink or smoke when using this product. P330:Rinse mouth. P301+P317:IF SWALLOWED: Get medical help. |
Starting at $172.90
1. Burns CM, Wortmann RL. (2011) Gout therapeutics: new drugs for an old disease.. Lancet, 377 (9760): (165-77). [PMID:20719377] |